Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abivertinib in EGFR T790M+ NSCLC
NCT02448251Phase 1Terminated
- Sponsor
- ACEA Therapeutics
- Start
- May 2015
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of abivertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by ACEA Therapeutics. Primary endpoints: Maximum Tolerated Dose at 28 days and Safety and Tolerability at 28 days. Started May 2015; status: terminated.
02
Drugs
abivertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02448251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02448251.